ChronicleBio is a techbio startup focused on radically accelerating insights on neuroimmune disorders. Founded in 2025, the company is headquartered in West Valley City, UT with 9 total employees. ChronicleBio operates in the biotechnology and precision medicine sector, specifically targeting historically overlooked neuroimmune conditions.
The company develops an AI-driven techbio platform that aggregates and analyzes multi-omic, clinical, and patient-reported data for complex neuroimmune disorders, with a focus on conditions such as POTS, ME/CFS, Long COVID, MCAS, Sjögren's, and Lyme-related illnesses. ChronicleBio has raised $5.36M from investors including Electric Capital, Tarsadia Investments, and Wisdom Ventures Fund.
Recent Leadership News
In June 2026, ChronicleBio appointed John Mumm, Ph.D., as Chief Scientific Officer, bringing three decades of immunology expertise and drug-development leadership from roles including founder of Deka Biosciences and participation in ARMO BioSciences, which was acquired by Eli Lilly for $1.6 billion.
Facts compiled by Executive Moves from publicly available news and press releases on 12 June 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the ChronicleBio team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
